# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses o...
- SEC Filing
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...
Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The n...
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expan...
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Stifel analyst Brad Canino initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Tar...
Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at ba...
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company r...